Advertisment

Promising Developments in Obesity Treatment: Amgen's Experimental Drug Shows Significant Results

author-image
Dr. Jessica Nelson
New Update
Promising Developments in Obesity Treatment: Amgen's Experimental Drug Shows Significant Results

Promising Developments in Obesity Treatment: Amgen's Experimental Drug Shows Significant Results

Advertisment

There are promising developments in the treatment of obesity, with Amgen's experimental drug, Maridebart cafraglutide, also known as AMG 133, showing significant results in both animal and early-stage human trials. The drug demonstrated notable weight loss and an acceptable safety profile, according to a medical journal publication. These findings could have significant implications for the treatment of obesity and related health conditions.

Advertisment

Maridebart Cafraglutide: A Novel Approach to Obesity Management

AMG 133 is a novel drug developed by Amgen aimed at tackling obesity. The preliminary results from animal and early-stage human trials have shown promising results, with an average weight loss of 14.5% sustained for up to 70 days. Furthermore, the drug demonstrated an acceptable safety and tolerability profile in its Phase 1 trial, with mild side effects that resolved on their own.

The drug targets two key hormones involved in appetite control and metabolic regulation. If the drug's effectiveness continues to hold in subsequent trials, it could offer a more effective and safer treatment alternative for obesity. However, further research is necessary to confirm the drug's efficacy and safety profile in a larger population and over a longer period.

Advertisment

Phase 2 Trial and Future Implications

Amgen is currently conducting a Phase 2 trial for Maridebart cafraglutide, with results expected later this year. If these trials yield positive results, it could position AMG 133 as a key player in the obesity care space. Amgen has raised its revenue guidance for 2023 and is actively recruiting a Clinical Research Medical Director to oversee the global development program of AMG 133.

In light of the promising early data, Amgen's shares rose 1.21% to $327.11 premarket. The company's stock has risen approximately 32% in the last 12 months. The data published detailed outcomes and adverse events for 49 obese patients without underlying health conditions.

Advertisment

Competitive Landscape

While Amgen is making strides with its experimental drug, other companies are also making moves in the obesity treatment space. Novo Holdings, the parent of Novo Nordisk, has recently acquired contract drugmaker Catalent for $11.5 billion in cash. This move is designed to help meet the strong demand for its popular weight-loss drug Wegovy. On the other hand, shares of mental healthcare provider LifeStance fell 5.8% after Hindenburg Research took a short position on the company's stock, and Cano Health filed for Chapter 11 bankruptcy to reduce debt and solicit potential offers, including the sale of the firm.

Finally, the development of Amgen's experimental obesity drug, Maridebart cafraglutide, shows promising potential in the treatment of obesity. If the efficacy and safety of the drug continue to hold in subsequent trials, it could significantly impact the obesity care space. However, further research is necessary to confirm these promising results.

Weight Loss Obesity
Advertisment
Chat with Dr. Medriva !